ConductScience.org, home

Paper28629344

Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis.

Tanaka M and 4 others. BMC Musculoskelet Disord, 2017. Cited by 19 papers, by iCite.

Cite this record

ConductScience Library. Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis. Papers, record 28629344. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28629344

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis.
PubMed
Journal
BMC Musculoskelet Disord
PubMed
Year
2017
PubMed
Publication types
Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial
PubMed
Citations, by iCite
19
iCite
Relative citation ratio, by iCite
0.85
iCite
Revised in PubMed
2025-05-30
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tanaka MMakoto
2Hashimoto YYoshitaka
3Hasegawa CChihiro
4Deacon SSteve
5Eastell RRichard

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Bone DensityMajor topic
Bone Density Conservation AgentsMajor topic
Cathepsin KMajor topic
Osteoporosis, PostmenopausalMajor topic
ThiazolidinesMajor topic
Aged
Double-Blind Method
Female
Humans
Middle Aged
Treatment Outcome

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
MR/P020941/1Medical Research CouncilUnited KingdomPubMed

Source PubMed

Download CSV of grants

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
18703060Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency.Science1996https://conductscience.org/library/papers/8703060PubMed
216509577Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors.J Med Chem2006https://conductscience.org/library/papers/16509577PubMed
322533981Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women.Br J Clin Pharmacol2012https://conductscience.org/library/papers/22533981PubMed
410968780Bone resorption by osteoclasts.Science2000https://conductscience.org/library/papers/10968780PubMed
515876399The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.Adv Drug Deliv Rev2005https://conductscience.org/library/papers/15876399PubMed
610968781Therapeutic approaches to bone diseases.Science2000https://conductscience.org/library/papers/10968781PubMed
712733725The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation.J Bone Miner Res2003https://conductscience.org/library/papers/12733725PubMed
823013236Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.Br J Clin Pharmacol2013https://conductscience.org/library/papers/23013236PubMed
918248311The influence of circadian rhythms on the kinetics of drugs in humans.Expert Opin Drug Metab Toxicol2008https://conductscience.org/library/papers/18248311PubMed
1012110413Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting.Bone2002https://conductscience.org/library/papers/12110413PubMed
118288568Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts.J Biol Chem1994https://conductscience.org/library/papers/8288568PubMed
128506892Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis.Am J Med1993https://conductscience.org/library/papers/8506892PubMed
1322113921Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey.J Bone Miner Res2012https://conductscience.org/library/papers/22113921PubMed
1410571690Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation.J Bone Miner Res1999https://conductscience.org/library/papers/10571690PubMed
1521380636Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys.Osteoporos Int2012https://conductscience.org/library/papers/21380636PubMed
1624915115Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis.J Clin Endocrinol Metab2014https://conductscience.org/library/papers/24915115PubMed
179811821Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice.Proc Natl Acad Sci U S A1998https://conductscience.org/library/papers/9811821PubMed
1826188109An oral cathepsin K inhibitor ONO-5334 inhibits N-terminal and C-terminal collagen crosslinks in serum and urine at similar plasma concentrations in postmenopausal women.Bone2015https://conductscience.org/library/papers/26188109PubMed
1918293146Clinical chronopharmacology in the elderly.Chronobiol Int2008https://conductscience.org/library/papers/18293146PubMed
2021982869Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism.Bone2011https://conductscience.org/library/papers/21982869PubMed

See all 37 referencesDownload CSV of references

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.

PMIDTitleJournalYearIn PapersSource
41607468Bidirectional crosstalk between the bone extracellular matrix and lysosomes in bone remodeling and osteoporosis.Front Endocrinol (Lausanne)2025https://conductscience.org/library/papers/41607468PubMed
39957690Proteases and Osteoporosis: A Comprehensive Review of Their Role in Bone Health.Curr Drug Targets2025https://conductscience.org/library/papers/39957690PubMed
35912093Cathepsin K+ Non-Osteoclast Cells in the Skeletal System: Function, Models, Identity, and Therapeutic Implications.Front Cell Dev Biol2022https://conductscience.org/library/papers/35912093PubMed
35265628The Mechanosensory Role of Osteocytes and Implications for Bone Health and Disease States.Front Cell Dev Biol2021https://conductscience.org/library/papers/35265628PubMed
35163315Therapeutic Treatments for Osteoporosis-Which Combination of Pills Is the Best among the Bad?Int J Mol Sci2022https://conductscience.org/library/papers/35163315PubMed
34604343Bone Quality in Chronic Kidney Disease Patients: Current Concepts and Future Directions - Part II.Kidney Dis (Basel)2021https://conductscience.org/library/papers/34604343PubMed
32582709Cathepsin K: The Action in and Beyond Bone.Front Cell Dev Biol2020https://conductscience.org/library/papers/32582709PubMed
31980525Reassessing enzyme kinetics: Considering protease-as-substrate interactions in proteolytic networks.Proc Natl Acad Sci U S A2020https://conductscience.org/library/papers/31980525PubMed
30663085Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.Br J Clin Pharmacol2019https://conductscience.org/library/papers/30663085PubMed
29723068Advances in the discovery of cathepsin K inhibitors on bone resorption.J Enzyme Inhib Med Chem2018https://conductscience.org/library/papers/29723068PubMed
29721251Bone-targeted agents in multiple myeloma.Hematol Rep2018https://conductscience.org/library/papers/29721251PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CTSK1513PubTator's text mininghttps://conductscience.org/library/genes/1513NCBI Gene
CYP27A11593PubTator's text mininghttps://conductscience.org/library/genes/1593NCBI Gene
PTH5741PubTator's text mininghttps://conductscience.org/library/genes/5741NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28629344

GET https://conductscience.org/api/papers/v1/28629344/references?page=2